1. Home
  2. LENZ vs ELTX Comparison

LENZ vs ELTX Comparison

Compare LENZ & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LENZ Therapeutics Inc.

LENZ

LENZ Therapeutics Inc.

HOLD

Current Price

$5.57

Market Cap

198.8M

Sector

Health Care

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$3.98

Market Cap

185.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LENZ
ELTX
Founded
2019
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.8M
185.4M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
LENZ
ELTX
Price
$5.57
$3.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$44.00
$18.00
AVG Volume (30 Days)
610.6K
3.2M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
$19,088,000.00
$2,301,000.00
Revenue This Year
$50.42
N/A
Revenue Next Year
$197.16
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.73
$2.66
52 Week High
$50.19
$16.00

Technical Indicators

Market Signals
Indicator
LENZ
ELTX
Relative Strength Index (RSI) 26.32 32.52
Support Level N/A $2.66
Resistance Level $10.42 $9.95
Average True Range (ATR) 0.43 1.43
MACD -0.05 -0.94
Stochastic Oscillator 0.56 9.60

Price Performance

Historical Comparison
LENZ
ELTX

About LENZ LENZ Therapeutics Inc.

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: